The chemical class of potential DOCK180 activators is diverse, primarily consisting of inhibitors targeting key components of pathways associated with DOCK180 function. Since direct activators are scarce, these chemicals offer an indirect approach to modulate DOCK180 activity by influencing the cellular context in which DOCK180 operates. The majority of these compounds interact with small GTPases or their regulators. For instance, inhibitors like NSC23766, EHop-016, ML141, and ZCL278 focus on Rac1 or Cdc42, GTPases that are pivotal in the actin cytoskeleton dynamics, a major area of DOCK180's influence. By modulating these GTPases, these compounds indirectly affect the signaling cascades that DOCK180 participates in, especially in processes like cell migration and phagocytosis.
In summary, while direct chemical activators of DOCK180 are not widely recognized, a range of compounds can be employed to indirectly influence its activity. This approach relies on understanding and targeting the broader signaling networks and cellular processes associated with DOCK180 function, offering a strategic method to modulate its activity in a cellular context. The chemicals listed here represent a cross-section of this strategy, highlighting the multifaceted nature of modulating protein functions indirectly through related pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
EHop-016 | 1380432-32-5 | sc-497382 | 5 mg | $80.00 | ||
Targets Rac1, potentially altering DOCK180 mediated actin cytoskeleton rearrangement. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
Cdc42 inhibitor, indirectly affecting DOCK180 related pathways involving Cdc42. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
Inhibits Cdc42, potentially influencing pathways related to DOCK180. | ||||||
CASIN | 425399-05-9 | sc-397016 | 10 mg | $460.00 | 1 | |
Inhibits Cdc42 activation, which may impact DOCK180-related signaling pathways. | ||||||
GSK 269962 | 850664-21-0 | sc-363279 sc-363279A | 10 mg 50 mg | $300.00 $1000.00 | 1 | |
ROCK inhibitor, potentially affecting actin dynamics associated with DOCK180. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor, may influence actin cytoskeleton rearrangement relevant to DOCK180. | ||||||
IPA 3 | 42521-82-4 | sc-204016 sc-204016A | 5 mg 50 mg | $94.00 $458.00 | 6 | |
Selective inhibitor of PAK1, indirectly affecting DOCK180-related signaling. | ||||||
SL 0101-1 | 77307-50-7 | sc-204287 sc-204287A sc-204287B sc-204287C sc-204287D | 1 mg 10 mg 25 mg 50 mg 100 mg | $200.00 $353.00 $772.00 $1230.00 $2070.00 | 3 | |
Inhibits RSK, potentially impacting downstream effects of DOCK180. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
BMP signaling inhibitor, might affect cellular processes related to DOCK180 function. | ||||||